T1	Participants 70 88	high-risk patients
T2	Participants 30 45	corticosteroids
T3	Participants 246 289	high-risk patients with long-bone fractures
T4	Participants 410 474	corticosteroid- (0 of 21) and placebo-treated patients (9 of 41)
T5	Participants 158 179	fat embolism syndrome
